Hlectron (pronounced “E-lectron) develops medical systems that utilise the power of Magnetic Nanotechnology, Quantum Spin Bio-Chemistry and electromagnetism to improve the outcome of cancer treatment through enhanced and targeted free radical action.

The development of our innovative technology started more than a decade ago at the Cavendish Laboratory (Department of Physics) of The University of Cambridge. Our clinical data demonstrate the efficacy of Hlectron’s protocols and their potential to increase survival rates of patients with breast cancer, advanced breast cancer, as well as  other cancer types.

Our medical systems, MagTherm and NanoMagTherm, are the outcome of large international, multidisciplinary business innovation research projects. The underpinning technology is based on targeted oxidative stress assault on cancer cells in combination with electromagnetic irradiation, to induce tumour cell death (apoptosis). As an upgrade of MagThem, NanoMagTherm is a system for cancer treatment with the potential to replace systemic chemotherapy, thus minimizing side effects and disruptively improving clinical outcome/quality of life and reducing economic burden. MagTherm has undergone successful human clinical trials, whilst NanoMagTherm has completed successful animal trials.